Irbesartan Canon, 150 mg tablets 14 pcs

Disorders of water-electrolyte balance. Before Irbesartan Canon administration in patients with decreased BOD (including due to diarrhea or vomiting, intensive therapy with diuretics, diet with restriction of table salt intake) it is necessary to restore circulating blood volume, eliminate hyponatremia, because there is a risk of symptomatic arterial hypotension, especially after the first dose.

Renovascular hypertension. There is a potentially increased risk of severe arterial hypotension and renal failure in patients with bilateral renal artery stenosis or arterial stenosis of the only functioning kidney.

Kidney failure and renal transplantation. Monitoring of serum potassium and creatinine in patients with renal insufficiency is recommended. There are no clinical data regarding the use of irbesartan in patients after renal transplantation.

Patients with arterial hypertension and type 2 diabetes with impaired renal function.

The beneficial effects noted for irbesartan in slowing the progression of renal and cardiovascular events vary among patient groups, being less pronounced in women and in patients who are not Caucasian.

Double RAAS blockade when combining irbesartan with ACE inhibitors or with aliskiren

Dual RAS blockade in combination with ACE inhibitors or aliskiren is not recommended because compared to monotherapy there is an increased risk of BP depression, hyperkalemia and renal dysfunction.

The use of Irbesartan Canon in combination with aliskiren is contraindicated in patients with diabetes mellitus or renal insufficiency with a GFR < 60 ml/min/1.73 m2 body surface area) and is not recommended in other patients.

The use of Irbesartan Canon in combination with ACE inhibitors is contraindicated in patients with diabetic nephropathy and is not recommended in other patients.

Hyperkalemia. It is recommended to monitor potassium content in patients concomitantly taking potassium preparations, potassium-saving diuretics, heparin, especially in the presence of renal failure and/or cardiovascular diseases with the drug Irbesartan Canon.

Aortic and mitral valve stenosis, GOCMP. As with any vasodilators, Irbesartan Canon should be used with caution.

Primary hyperaldosteronism. The use of Irbesartan Canon in primary hyperaldosteronism is inadvisable.

Other. In patients whose vascular tone and renal function is mainly dependent on the activity of RAAS (e.g. patients with chronic heart failure of III-IV functional class according to NYHA classification, concomitant renal diseases, including renal artery stenosis), therapy with ACE inhibitors or angiotensin II receptor antagonists is accompanied with the development of arterial hypotension, azotemia, oliguria and, rarely, acute renal failure. As with other hypotensive drugs, a significant decrease in BP in patients with CHD and/or atherosclerotic cerebral vascular lesions may lead to myocardial infarction, stroke. BP should be strictly monitored while treating such patients.

During treatment, caution should be exercised when driving motor vehicles and engaging in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions. In case of dizziness and weakness, there may be decreased attention and slow psychomotor reactions. In patients who have such adverse reactions, the decision about the possibility of engaging in any potentially dangerous activities should be made by the physician individually.

– Hypersensitivity to irbesartan or any component of the drug.

– Concomitant use with drugs containing aliskiren in patients with diabetes mellitus or with moderate to severe renal impairment (glomerular filtration rate [GFR] < 60 ml/min/1.73 m2 body surface area).

– Concomitant use with ACE inhibitors in patients with diabetic nephropathy.

– Hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

– Pregnancy.

– Period of lactation.

– Age under 18 years (effectiveness and safety not established).

– In severe hepatic failure (functional class C or greater than 9 points on the Child-Pugh scale) (no experience with clinical use).

– In aortic or mitral valve stenosis or hypertrophic obstructive cardiomyopathy (HCMP).

– In hypovolemia, hyponatremia, occurring, for example, with intensive treatment with diuretics, hemodialysis, diet with restriction of table salt intake, diarrhea, vomiting (risk of excessive BP reduction, especially with the first dose).

– In bilateral renal artery stenosis, unilateral artery stenosis of the only functioning kidney, chronic heart failure III-IV functional class (according to NYHA classification) (when treating such patients with drugs that affect the RAAS, observed: excessive BP reduction, oliguria and/or progressive azotemia, and rarely acute renal failure and/or death, the risk of which cannot be excluded with irbesartan as well).

– In coronary heart disease and/or clinically significant cerebral vascular atherosclerosis (with excessive BP reduction there is a risk of increased ischemic disturbances, up to the development of acute myocardial infarction and stroke).

– In renal failure (requires monitoring of potassium and creatinine concentration in the blood), recent kidney transplantation (no experience in clinical use).

– In severe hepatic impairment (functional class C or greater than 9 points on the Child-Pugh scale) (no experience with clinical use).

– With concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase 2 (COX-2) inhibitors (increased risk of impaired renal function, including the possibility of acute renal failure and increased serum potassium, especially in patients with already impaired renal function).

– When used in combination with ACE inhibitors or aliskiren, as compared to monotherapy with dual RAAS blockade, there is an increased risk of developing excessive BP reduction, hyperkalemia, and impaired renal function.

Patients over 75 years of age.